Health Ministry Recommends Stopping 2 Flu Vaccines After South Korean Deaths, Health News & Top Stories



[ad_1]

Local health authorities have advised against the use of two influenza vaccines, SKYCellflu Quadrivalent and VaxigripTetra, after several people died after receiving them in South Korea.

There were no deaths associated with influenza vaccination here, the Ministry of Health (MOH) and the Health Sciences Authority (HSA) noted yesterday, adding: “This is a precautionary measure after the deaths reported after of influenza vaccination in South Korea “.

The Straits Times previously reported that there were 36 deaths in South Korea as of Friday.

Information from South Korean authorities indicated that seven brands of influenza vaccine had been administered to people who died in South Korea.

Two of the seven brands are available in Singapore: SKYCellflu Quadrivalent is manufactured by SK Bioscience and distributed here by AJ Biologics; VaxigripTetra is produced by Sanofi Pasteur and distributed locally by Sanofi Aventis.

The HSA is evaluating the implications of the deaths reported in South Korea and the Health Ministry has told healthcare providers and doctors to temporarily stop using the two vaccines.

But the other two vaccines that have been brought to Singapore for the flu season can still be used, they added.

Like any medicine, vaccines can cause side effects, such as pain and redness at the injection site, fever, headaches, muscle aches, fatigue, and nausea.

“These side effects are generally mild and resolve on their own. On rare occasions, a person may experience a high fever or severe allergic reactions (such as shortness of breath, wheezing, and swelling around the eyes) and should seek immediate medical attention.” , He said. agencies. They added that the vaccines approved for use here have been evaluated by the HSA to ensure they meet required international standards for quality, safety and efficacy.

The HSA monitors vaccine safety through a monitoring system that relies on the network of local health professionals and international regulatory partners to detect adverse events suspected of being associated with the drugs.

LISTEN TO PODCAST HEALTH CONTROL



[ad_2]